Involvement of the JAK-STAT pathway in the molecular landscape of tyrosine kinase fusion-negative hypereosinophilic syndromes: A nationwide CEREO study.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
02 Apr 2024
02 Apr 2024
Historique:
received:
04
03
2024
accepted:
11
03
2024
medline:
2
4
2024
pubmed:
2
4
2024
entrez:
2
4
2024
Statut:
aheadofprint
Résumé
We investigated using a custom NGS panel of 149 genes the mutational landscape of 64 consecutive adult patients with tyrosine kinase fusion-negative hypereosinophilia (HE)/hypereosinophilic syndrome (HES) harboring features suggestive of myeloid neoplasm. At least one mutation was reported in 50/64 (78%) patients (compared to 8/44 (18%) patients with idiopathic HE/HES/HE
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Valent P, Klion AD, Roufosse F, et al. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. Allergy. 2023;78(1):47‐59.
Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200‐1228.
Klion AD. How I treat hypereosinophilic syndromes. Blood. 2015;126(9):1069‐1077.
Wang SA, Tam W, Tsai AG, et al. Targeted next‐generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol. 2016;29(8):854‐864.
Lee J‐S, Seo H, Im K, et al. Idiopathic hypereosinophilia is clonal disorder? Clonality identified by targeted sequencing. PloS One. 2017;12(10):e0185602.
Pardanani A, Lasho T, Wassie E, et al. Predictors of survival in WHO‐defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next‐generation sequencing. Leukemia. 2016;30(9):1924‐1926.
Dougan M, Dranoff G, Dougan SK. GM‐CSF, IL‐3, and IL‐5 family of cytokines: regulators of inflammation. Immunity. 2019;50(4):796‐811.
Ma CA, Xi L, Cauff B, et al. Somatic STAT5b gain‐of‐function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea. Blood. 2017;129(5):650‐653.
Cross NCP, Hoade Y, Tapper WJ, et al. Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia. Leukemia. 2019;33(2):415‐425.
Patel AB, Franzini A, Leroy E, et al. JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Blood. 2019;134(26):2388‐2398.
Shomali W, Damnernsawad A, Theparee T, et al. A novel activating JAK1 mutation in chronic eosinophilic leukemia. Blood Adv. 2021;5(18):3581‐3586.
Del Bel KL, Ragotte RJ, Saferali A, et al. JAK1 gain‐of‐function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome. J Allergy Clin Immunol. 2017;139(6):2016‐2020.e5.
Elling C, Erben P, Walz C, et al. Novel imatinib‐sensitive PDGFRA‐activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia‐like disease. Blood. 2011;117(10):2935‐2943.
Groh M, Rohmer J, Etienne N, et al. French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes. Orphanet J Rare Dis. 2023;18(1):100.
Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454‐2465.
Bernard E, Tuechler H, Greenberg PL, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1(7):EVIDoa2200008.
Jaiswal S, Fontanillas P, Flannick J, et al. Age‐related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488‐2498.
Wang SA, Orazi A, Gotlib J, et al. The international consensus classification of eosinophilic disorders and systemic mastocytosis. Am J Hematol. 2023;98(8):1286‐1306.
Gandhi NA, Bennett BL, Graham NMH, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35‐50.
Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndromes: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124(6):1319‐1325.e3.
Rohmer J, Couteau‐Chardon A, Trichereau J, et al. Epidemiology, clinical picture and long‐term outcomes of FIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia: data from 151 patients. Am J Hematol. 2020;95(11):1314‐1323.
Leurs A, Chenivesse C, Lopez B, et al. C‐reactive protein as a diagnostic tool in differential diagnosis of hypereosinophilic syndrome and antineutrophil cytoplasmic antibody‐negative eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract. 2019;7(4):1347‐1351.e3.
Schwaab J, Umbach R, Metzgeroth G, et al. KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance. Am J Hematol. 2015;90(9):774‐777.
de Araujo ED, Erdogan F, Neubauer HA, et al. Structural and functional consequences of the STAT5BN642H driver mutation. Nat Commun. 2019;10(1):2517.
Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF. Fetal anemia and apoptosis of red cell progenitors in Stat5a−/−5b−/− mice: a direct role for Stat5 in Bcl‐X(L) induction. Cell. 1999;98(2):181‐191.
Socolovsky M, Nam H, Fleming MD, et al. Ineffective erythropoiesis in Stat5a−/−5b−/− mice due to decreased survival of early erythroblasts. Blood. 2001;98(12):3261‐3273.
Constantinescu SN, Ghaffari S, Lodish HF. The erythropoietin receptor: structure, activation and intracellular signal transduction. Trends Endocrinol Metab. 1999;10(1):18‐23.
Schuringa JJ, Chung KY, Morrone G, Moore MAS. Constitutive activation of STAT5A promotes human hematopoietic stem cell self‐renewal and erythroid differentiation. J Exp Med. 2004;200(5):623‐635.
Tennenbaum J, Groh M, Venditti L, et al. FIP1L1‐PDGFRA‐associated hypereosinophilic syndrome as a treatable cause of watershed infarction. Stroke. 2021;52(10):e605‐e609.
Gaillet A, Bay P, Péju E, et al. Epidemiology, clinical presentation, and outcomes of 620 patients with eosinophilia in the intensive care unit. Intensive Care Med. 2023;49(3):291‐301.
Yin CC, Tam W, Walker SM, et al. STAT5B mutations in myeloid neoplasms differ by disease subtypes but characterize a subset of chronic myeloid neoplasms with eosinophilia and/or basophilia. Haematologica. 2023. doi:10.3324/haematol.2023.284311. Epub ahead of print.
Gerds AT, Gotlib J, Bose P, et al. Myeloid/lymphoid neoplasms with eosinophilia and TK fusion genes, version 3.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(9):1248‐1269.
Roufosse F, Kahn J‐E, Rothenberg ME, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo‐controlled trial. J Allergy Clin Immunol. 2020;146(6):1397‐1405.
Kuang FL, Legrand F, Makiya M, et al. Benralizumab for PDGFRA‐negative Hypereosinophilic syndrome. N Engl J Med. 2019;380(14):1336‐1346.
Knudsen TA, Hansen DL, Ocias LF, et al. Final analysis of the Daliah trial: a randomized phase III trial of interferon‐α versus hydroxyurea in patients with MPN. Blood. 2023;142(suppl 1):746.
Hasselbalch HC, Skov V, Kjaer L, Larsen MK. Proof of concept of triple COMBI therapy to prohibit MPN progression to AML. Br J Haematol. 2024;204(1):16‐18.